Tuesday, June 25, 2024
10:37 AM EST – Sernova Corp. : Announces developments in its Phase I/II clinical trial investigating a novel treatment for Type 1 Diabetes (T1D). To date a total of seven patients across Cohorts 1 and 2 have achieved insulin independence following transplants of human donor islets via Sernova’s proprietary Cell Pouch System™ and a marginal portal vein top up. Additionally, the study, which is being conducted at the University of Chicago, completed full enrollment of the second cohort of patients with the last patient being enrolled June 24. Sernova Corp. (T.SVA) shares were up $0.02 at 0.39.
Stocks in Play: Sernova Corp., Tue, 25 Jun 2024 10:42:06 EST